Immunophenotype, classification, and response to IL-7 of 21 patients with T-ALL
| Patients . | CD2 . | CD5 . | CD7 . | CD3 . | CD4 . | CD8 . | Stage . | Viability response to IL-7 . | Proliferative response to IL-7 . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | + | + | − | − | III | ND | + |
| 2 | + | + | + | + | + | + | III | − | − |
| 3 | + | + | + | − | + | + | II | + | + |
| 4 | + | + | + | + | − | − | III | + | + |
| 5 | + | + | + | + | − | − | III | + | + |
| 6 | − | ND | + | + | + | − | III | ND | − |
| 7 | + | + | + | − | + | − | II | + | + |
| 8 | + | + | + | − | + | + | II | ND | + |
| 9 | + | + | + | + | ND | + | III | − | − |
| 10 | + | + | + | + | − | + | III | + | − |
| 11 | + | + | + | + | − | + | III | + | − |
| 12 | ND | + | + | − | ND | − | II | ND | + |
| 13 | + | + | + | + | − | − | III | + | + |
| 14 | − | + | + | + | + | − | III | + | + |
| 15 | − | + | + | − | + | − | II | ND | − |
| 16 | + | + | + | − | − | + | II | ND | + |
| 17 | + | + | + | − | + | − | II | + | + |
| 18 | + | + | + | + | + | + | III | ND | + |
| 19 | + | + | + | − | + | + | II | + | + |
| 20 | + | + | + | + | + | − | III | ND | + |
| 21 | + | + | + | + | − | + | III | ND | − |
| Patients . | CD2 . | CD5 . | CD7 . | CD3 . | CD4 . | CD8 . | Stage . | Viability response to IL-7 . | Proliferative response to IL-7 . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | + | + | − | − | III | ND | + |
| 2 | + | + | + | + | + | + | III | − | − |
| 3 | + | + | + | − | + | + | II | + | + |
| 4 | + | + | + | + | − | − | III | + | + |
| 5 | + | + | + | + | − | − | III | + | + |
| 6 | − | ND | + | + | + | − | III | ND | − |
| 7 | + | + | + | − | + | − | II | + | + |
| 8 | + | + | + | − | + | + | II | ND | + |
| 9 | + | + | + | + | ND | + | III | − | − |
| 10 | + | + | + | + | − | + | III | + | − |
| 11 | + | + | + | + | − | + | III | + | − |
| 12 | ND | + | + | − | ND | − | II | ND | + |
| 13 | + | + | + | + | − | − | III | + | + |
| 14 | − | + | + | + | + | − | III | + | + |
| 15 | − | + | + | − | + | − | II | ND | − |
| 16 | + | + | + | − | − | + | II | ND | + |
| 17 | + | + | + | − | + | − | II | + | + |
| 18 | + | + | + | + | + | + | III | ND | + |
| 19 | + | + | + | − | + | + | II | + | + |
| 20 | + | + | + | + | + | − | III | ND | + |
| 21 | + | + | + | + | − | + | III | ND | − |
T-cell maturation stages were defined as described17: Stage I (Pro-TL): CD7+CD2−CD5−CD3−; Stage II (Immature TL): CD7+ (CD2 and/or CD5)+ CD3−; Stage III (mature TL): CD7+ CD2+CD5+ CD3+.
IL-7 indicates interleukin-7; T-ALL, T-cell acute lymphoblastic leukemia; ND, not determined.